Half-year report · Q2
2533.TEDINET S100U4VC
Period2024-01-01 → 2024-06-30
Filed2024-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥40.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Revenue | ¥84.9bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥42.7bn | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Operating income | ¥1.6bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Operating income | ¥2.0bn | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.7bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.7bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.1bn | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.7bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.1bn | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.3bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.3bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Net income | ¥1.7bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Total assets | ¥56.0bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥55.4bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥51.9bn | at 2023-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥32.7bn | at 2024-06-30 | Cons. | Liabilities |
| Total liabilities | ¥33.2bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥23.3bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥22.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.4bn | at 2023-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥986m | at 2024-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥828m | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥982m | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥824m | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥616m | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥894m | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥495m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.6bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥94m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥752m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥11m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥532m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥414m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.7bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥716m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥21.81 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.3 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.52 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.0% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-06-30 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-06-30 | ¥7m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥19m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥19m |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥363m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥37.4bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥37.4bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥14m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥903m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥567m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥567m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥298m |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥40.2bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥40.2bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥14m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-06-30 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-06-30 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-06-30 | ¥2m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥13m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥13m |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥1.8bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥1.8bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥360m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥38.8bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥38.8bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥13m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥662m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥662m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥352m |
| jpcrp040300-q2r_E00397-000Starch For Processingreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q2r_E00397-000Starch For Processingreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q2r_E00397-000Starch For Processingreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥6m |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥42.6bn |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥42.6bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥13m |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 583
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 14000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -19000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 37396000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | 2248000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | 567000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 40212000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 46000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -19000000 | JPY |
| Net sales | CurrentYTDDuration | 40239000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 903000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | 363000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | 298000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 1565000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 7000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 1572000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-08-07 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第118期中(自 令和６年１月１日 至 令和６年６月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)オエノンホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Oenon Holdings, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 西 永 裕 司 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都墨田区東駒形一丁目17番６号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03（6757）4580 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 西 永 裕 司 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都墨田区東駒形一丁目17番６号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03（6757）4580 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 西 永 裕 司 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00397 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 25330 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)オエノンホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Oenon Holdings, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-06-30 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |